A settlement has been reached in a whistleblower class action lawsuit brought against CareFusion Corp who is accused of paying kickbacks and promoting its products for uses that were not approved by the Food and Drug Administration.
The whistleblower's share in this case is $3.26 million.
The originally filed lawsuit began in September 2010. The government's case against CareFusion alleged that, under agreements entered into in 2008 by CareFusion’s predecessor, CareFusion paid $11.6 million in kickbacks to Dr. Charles Denham while Denham served as the co-chair of the Safe Practices Committee at the National Quality Forum. National Quality Forum is a non-profit organization that reviews, endorses and recommends standardized health care performance measures and practices. The government contends that the purpose of those payments was to induce Denham to recommend, promote and arrange for the purchase of ChloraPrep by health care providers. ChloraPrep has been approved by the Food and Drug Administration for the preparation of a patient’s skin prior to surgery or injection.
The complaint further made claims that, during the period between September 2009 and August 2011, CareFusion knowingly promoted the sale of ChloraPrep for uses that were not approved by the Food and Drug Administration, some of which were not medically accepted indications, and made unsubstantiated representations about the appropriate uses of ChloraPrep.
